APO Research
Talk to an analyst

APO RESEARCH · REPORT

Performance Enhancing Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Performance Enhancing Drugs Industry Growth and Trends Forecast to 2032

20 December 202597 pages

Choose your research edition.

Industry ResearchPerformance Enhancing Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Performance Enhancing Drugs Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Performance Enhancing Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Performance Enhancing Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Performance Enhancing Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Performance Enhancing Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Performance Enhancing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Performance Enhancing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Performance Enhancing Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Performance Enhancing Drugs include Eli Lilly And Company, Bayer, AstraZeneca, Taj Pharmaceuticals, Onnit Labs, Novo Nordisk, Douglas Laboratories, BrainAlert and Balkan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Performance Enhancing Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Performance Enhancing Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Performance Enhancing Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Performance Enhancing Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Performance Enhancing Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Performance Enhancing Drugs Market by Company

Eli Lilly And Company

Bayer

AstraZeneca

Taj Pharmaceuticals

Onnit Labs

Novo Nordisk

Douglas Laboratories

BrainAlert

Balkan Pharmaceuticals

Performance Enhancing Drugs Segment by Type

Patches

Pills

Injections

Performance Enhancing Drugs Segment by Application

Militaries

Students

Athletes

Others

Performance Enhancing Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Performance Enhancing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Performance Enhancing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Performance Enhancing Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Performance Enhancing Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Performance Enhancing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Patches Table 2. Major Company of Pills Table 3. Major Company of Injections Table 4. Global Performance Enhancing Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 6. Global Performance Enhancing Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Performance Enhancing Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Performance Enhancing Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global Performance Enhancing Drugs Sales by Type (2027-2032) & (K Units) Table 11. Global Performance Enhancing Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Performance Enhancing Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Performance Enhancing Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Performance Enhancing Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 16. North America Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 18. Europe Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 22. Latin America Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Performance Enhancing Drugs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa Performance Enhancing Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Performance Enhancing Drugs Industry Trends Table 26. Performance Enhancing Drugs Industry Drivers Table 27. Performance Enhancing Drugs Industry Opportunities and Challenges Table 28. Performance Enhancing Drugs Industry Restraints Table 29. Global Performance Enhancing Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Performance Enhancing Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Performance Enhancing Drugs Sales by Company (2021-2026) & (K Units) Table 32. Global Performance Enhancing Drugs Sales Share by Company (2021-2026) Table 33. Global Performance Enhancing Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global Performance Enhancing Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Performance Enhancing Drugs Major Company Production Sites and Headquarters Table 36. Global Performance Enhancing Drugs Company, Product Type & Application Table 37. Global Performance Enhancing Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Performance Enhancing Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Performance Enhancing Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Performance Enhancing Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global Performance Enhancing Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Performance Enhancing Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Performance Enhancing Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Performance Enhancing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global Performance Enhancing Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global Performance Enhancing Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Performance Enhancing Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Performance Enhancing Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Performance Enhancing Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global Performance Enhancing Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global Performance Enhancing Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Performance Enhancing Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Performance Enhancing Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Performance Enhancing Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global Performance Enhancing Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Performance Enhancing Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Performance Enhancing Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Performance Enhancing Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 63. North America Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 65. Europe Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 69. Latin America Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Performance Enhancing Drugs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa Performance Enhancing Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Eli Lilly And Company Company Information Table 73. Eli Lilly And Company Business Overview Table 74. Eli Lilly And Company Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Eli Lilly And Company Performance Enhancing Drugs Product Portfolio Table 76. Eli Lilly And Company Recent Development Table 77. Bayer Company Information Table 78. Bayer Business Overview Table 79. Bayer Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Bayer Performance Enhancing Drugs Product Portfolio Table 81. Bayer Recent Development Table 82. AstraZeneca Company Information Table 83. AstraZeneca Business Overview Table 84. AstraZeneca Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. AstraZeneca Performance Enhancing Drugs Product Portfolio Table 86. AstraZeneca Recent Development Table 87. Taj Pharmaceuticals Company Information Table 88. Taj Pharmaceuticals Business Overview Table 89. Taj Pharmaceuticals Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Taj Pharmaceuticals Performance Enhancing Drugs Product Portfolio Table 91. Taj Pharmaceuticals Recent Development Table 92. Onnit Labs Company Information Table 93. Onnit Labs Business Overview Table 94. Onnit Labs Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Onnit Labs Performance Enhancing Drugs Product Portfolio Table 96. Onnit Labs Recent Development Table 97. Novo Nordisk Company Information Table 98. Novo Nordisk Business Overview Table 99. Novo Nordisk Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Novo Nordisk Performance Enhancing Drugs Product Portfolio Table 101. Novo Nordisk Recent Development Table 102. Douglas Laboratories Company Information Table 103. Douglas Laboratories Business Overview Table 104. Douglas Laboratories Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Douglas Laboratories Performance Enhancing Drugs Product Portfolio Table 106. Douglas Laboratories Recent Development Table 107. BrainAlert Company Information Table 108. BrainAlert Business Overview Table 109. BrainAlert Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. BrainAlert Performance Enhancing Drugs Product Portfolio Table 111. BrainAlert Recent Development Table 112. Balkan Pharmaceuticals Company Information Table 113. Balkan Pharmaceuticals Business Overview Table 114. Balkan Pharmaceuticals Performance Enhancing Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Balkan Pharmaceuticals Performance Enhancing Drugs Product Portfolio Table 116. Balkan Pharmaceuticals Recent Development Table 117. North America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 118. North America Performance Enhancing Drugs Sales by Country (2021-2026) & (K Units) Table 119. North America Performance Enhancing Drugs Sales Market Share by Country (2021-2026) Table 120. North America Performance Enhancing Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 121. North America Performance Enhancing Drugs Sales Market Share Forecast by Country (2027-2032) Table 122. North America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 123. North America Performance Enhancing Drugs Market Size by Country (2021-2026) & (US$ Million) Table 124. North America Performance Enhancing Drugs Market Share by Country (2021-2026) Table 125. North America Performance Enhancing Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 126. North America Performance Enhancing Drugs Market Share Forecast by Country (2027-2032) Table 127. Europe Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 128. Europe Performance Enhancing Drugs Sales by Country (2021-2026) & (K Units) Table 129. Europe Performance Enhancing Drugs Sales Market Share by Country (2021-2026) Table 130. Europe Performance Enhancing Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 131. Europe Performance Enhancing Drugs Sales Market Share Forecast by Country (2027-2032) Table 132. Europe Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 133. Europe Performance Enhancing Drugs Market Size by Country (2021-2026) & (US$ Million) Table 134. Europe Performance Enhancing Drugs Market Share by Country (2021-2026) Table 135. Europe Performance Enhancing Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 136. Europe Performance Enhancing Drugs Market Share Forecast by Country (2027-2032) Table 137. Asia-Pacific Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. Asia-Pacific Performance Enhancing Drugs Sales by Country (2021-2026) & (K Units) Table 139. Asia-Pacific Performance Enhancing Drugs Sales Market Share by Country (2021-2026) Table 140. Asia-Pacific Performance Enhancing Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 141. Asia-Pacific Performance Enhancing Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. Asia-Pacific Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. Asia-Pacific Performance Enhancing Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. Asia-Pacific Performance Enhancing Drugs Market Share by Country (2021-2026) Table 145. Asia-Pacific Performance Enhancing Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. Asia-Pacific Performance Enhancing Drugs Market Share Forecast by Country (2027-2032) Table 147. Latin America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Latin America Performance Enhancing Drugs Sales by Country (2021-2026) & (K Units) Table 149. Latin America Performance Enhancing Drugs Sales Market Share by Country (2021-2026) Table 150. Latin America Performance Enhancing Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 151. Latin America Performance Enhancing Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Latin America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Latin America Performance Enhancing Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Latin America Performance Enhancing Drugs Market Share by Country (2021-2026) Table 155. Latin America Performance Enhancing Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Latin America Performance Enhancing Drugs Market Share Forecast by Country (2027-2032) Table 157. Middle East and Africa Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Middle East and Africa Performance Enhancing Drugs Sales by Country (2021-2026) & (K Units) Table 159. Middle East and Africa Performance Enhancing Drugs Sales Market Share by Country (2021-2026) Table 160. Middle East and Africa Performance Enhancing Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 161. Middle East and Africa Performance Enhancing Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. Middle East and Africa Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Middle East and Africa Performance Enhancing Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. Middle East and Africa Performance Enhancing Drugs Market Share by Country (2021-2026) Table 165. Middle East and Africa Performance Enhancing Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Middle East and Africa Performance Enhancing Drugs Market Share Forecast by Country (2027-2032) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Performance Enhancing Drugs Distributors List Table 170. Performance Enhancing Drugs Customers List Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Performance Enhancing Drugs Image Figure 2. Global Performance Enhancing Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Performance Enhancing Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Performance Enhancing Drugs Sales (2021-2032) & (K Units) Figure 5. Patches Image Figure 6. Global Patches Sales YoY Growth (2021-2032) & (K Units) Figure 7. Pills Image Figure 8. Global Pills Sales YoY Growth (2021-2032) & (K Units) Figure 9. Injections Image Figure 10. Global Injections Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global Performance Enhancing Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Performance Enhancing Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Performance Enhancing Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Performance Enhancing Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Performance Enhancing Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Performance Enhancing Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Performance Enhancing Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Performance Enhancing Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Performance Enhancing Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Performance Enhancing Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Performance Enhancing Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Performance Enhancing Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Performance Enhancing Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Militaries Image Figure 26. Global Militaries Sales YoY Growth (2021-2032) & (K Units) Figure 27. Students Image Figure 28. Global Students Sales YoY Growth (2021-2032) & (K Units) Figure 29. Athletes Image Figure 30. Global Athletes Sales YoY Growth (2021-2032) & (K Units) Figure 31. Others Image Figure 32. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Performance Enhancing Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Performance Enhancing Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Performance Enhancing Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Performance Enhancing Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Performance Enhancing Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Performance Enhancing Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Performance Enhancing Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Performance Enhancing Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Performance Enhancing Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Performance Enhancing Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Performance Enhancing Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Performance Enhancing Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Performance Enhancing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Performance Enhancing Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Performance Enhancing Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Performance Enhancing Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Performance Enhancing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Performance Enhancing Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Performance Enhancing Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Performance Enhancing Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Performance Enhancing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Performance Enhancing Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Performance Enhancing Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Performance Enhancing Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Performance Enhancing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Performance Enhancing Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Performance Enhancing Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Performance Enhancing Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Performance Enhancing Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Performance Enhancing Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Performance Enhancing Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Performance Enhancing Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Performance Enhancing Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Performance Enhancing Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Patches
  • Pills
  • Injections
Applications
  • Militaries
  • Students
  • Athletes
  • Others
Companies covered
  • Eli Lilly And Company
  • Bayer
  • AstraZeneca
  • Taj Pharmaceuticals
  • Onnit Labs
  • Novo Nordisk
  • Douglas Laboratories
  • BrainAlert
  • Balkan Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Performance Enhancing Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Performance Enhancing Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Performance Enhancing Drugs Market by Type
  6. 1.3.1 Patches
  7. 1.3.2 Pills
  8. 1.3.3 Injections
  9. 1.4 Global Performance Enhancing Drugs Market Size by Type
  10. 1.4.1 Global Performance Enhancing Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Performance Enhancing Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Performance Enhancing Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Performance Enhancing Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Performance Enhancing Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Performance Enhancing Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Performance Enhancing Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Performance Enhancing Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Performance Enhancing Drugs Industry Trends
  2. 2.2 Performance Enhancing Drugs Industry Drivers
  3. 2.3 Performance Enhancing Drugs Industry Opportunities and Challenges
  4. 2.4 Performance Enhancing Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Performance Enhancing Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Performance Enhancing Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Performance Enhancing Drugs Price (2021-2026)
  4. 3.4 Global Performance Enhancing Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Performance Enhancing Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Performance Enhancing Drugs Company, Product Type & Application
  7. 3.7 Global Performance Enhancing Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Performance Enhancing Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Performance Enhancing Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Performance Enhancing Drugs Tier 1, Tier 2, and Tier 3
4 Performance Enhancing Drugs Regional Status and Outlook
  1. 4.1 Global Performance Enhancing Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Performance Enhancing Drugs Historic Market Size by Region
  3. 4.2.1 Global Performance Enhancing Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Performance Enhancing Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Performance Enhancing Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Performance Enhancing Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Performance Enhancing Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Performance Enhancing Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Performance Enhancing Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Performance Enhancing Drugs by Application
  1. 5.1 Performance Enhancing Drugs Market by Application
  2. 5.1.1 Militaries
  3. 5.1.2 Students
  4. 5.1.3 Athletes
  5. 5.1.4 Others
  6. 5.2 Global Performance Enhancing Drugs Market Size by Application
  7. 5.2.1 Global Performance Enhancing Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Performance Enhancing Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Performance Enhancing Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Performance Enhancing Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Performance Enhancing Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Performance Enhancing Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Performance Enhancing Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Performance Enhancing Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly And Company
  2. 6.1.1 Eli Lilly And Company Company Information
  3. 6.1.2 Eli Lilly And Company Business Overview
  4. 6.1.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly And Company Performance Enhancing Drugs Product Portfolio
  6. 6.1.5 Eli Lilly And Company Recent Developments
  7. 6.2 Bayer
  8. 6.2.1 Bayer Company Information
  9. 6.2.2 Bayer Business Overview
  10. 6.2.3 Bayer Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer Performance Enhancing Drugs Product Portfolio
  12. 6.2.5 Bayer Recent Developments
  13. 6.3 AstraZeneca
  14. 6.3.1 AstraZeneca Company Information
  15. 6.3.2 AstraZeneca Business Overview
  16. 6.3.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 AstraZeneca Performance Enhancing Drugs Product Portfolio
  18. 6.3.5 AstraZeneca Recent Developments
  19. 6.4 Taj Pharmaceuticals
  20. 6.4.1 Taj Pharmaceuticals Company Information
  21. 6.4.2 Taj Pharmaceuticals Business Overview
  22. 6.4.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Taj Pharmaceuticals Performance Enhancing Drugs Product Portfolio
  24. 6.4.5 Taj Pharmaceuticals Recent Developments
  25. 6.5 Onnit Labs
  26. 6.5.1 Onnit Labs Company Information
  27. 6.5.2 Onnit Labs Business Overview
  28. 6.5.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Onnit Labs Performance Enhancing Drugs Product Portfolio
  30. 6.5.5 Onnit Labs Recent Developments
  31. 6.6 Novo Nordisk
  32. 6.6.1 Novo Nordisk Company Information
  33. 6.6.2 Novo Nordisk Business Overview
  34. 6.6.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novo Nordisk Performance Enhancing Drugs Product Portfolio
  36. 6.6.5 Novo Nordisk Recent Developments
  37. 6.7 Douglas Laboratories
  38. 6.7.1 Douglas Laboratories Company Information
  39. 6.7.2 Douglas Laboratories Business Overview
  40. 6.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Douglas Laboratories Performance Enhancing Drugs Product Portfolio
  42. 6.7.5 Douglas Laboratories Recent Developments
  43. 6.8 BrainAlert
  44. 6.8.1 BrainAlert Company Information
  45. 6.8.2 BrainAlert Business Overview
  46. 6.8.3 BrainAlert Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 BrainAlert Performance Enhancing Drugs Product Portfolio
  48. 6.8.5 BrainAlert Recent Developments
  49. 6.9 Balkan Pharmaceuticals
  50. 6.9.1 Balkan Pharmaceuticals Company Information
  51. 6.9.2 Balkan Pharmaceuticals Business Overview
  52. 6.9.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Balkan Pharmaceuticals Performance Enhancing Drugs Product Portfolio
  54. 6.9.5 Balkan Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Performance Enhancing Drugs Sales by Country
  2. 7.1.1 North America Performance Enhancing Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Performance Enhancing Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Performance Enhancing Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Performance Enhancing Drugs Market Size by Country
  6. 7.2.1 North America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Performance Enhancing Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Performance Enhancing Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Performance Enhancing Drugs Sales by Country
  2. 8.1.1 Europe Performance Enhancing Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Performance Enhancing Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Performance Enhancing Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Performance Enhancing Drugs Market Size by Country
  6. 8.2.1 Europe Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Performance Enhancing Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Performance Enhancing Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Performance Enhancing Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Performance Enhancing Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Performance Enhancing Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Performance Enhancing Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Performance Enhancing Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Performance Enhancing Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Performance Enhancing Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Performance Enhancing Drugs Sales by Country
  2. 10.1.1 South America Performance Enhancing Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Performance Enhancing Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Performance Enhancing Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Performance Enhancing Drugs Market Size by Country
  6. 10.2.1 South America Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Performance Enhancing Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Performance Enhancing Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Performance Enhancing Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Performance Enhancing Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Performance Enhancing Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Performance Enhancing Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Performance Enhancing Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Performance Enhancing Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Performance Enhancing Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Performance Enhancing Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Performance Enhancing Drugs Value Chain Analysis
  2. 12.1.1 Performance Enhancing Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Performance Enhancing Drugs Production Mode & Process
  7. 12.2 Performance Enhancing Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Performance Enhancing Drugs Distributors
  10. 12.2.3 Performance Enhancing Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst